Maternal cholestasis of pregnancy and fetal risks

Maternal cholestasis of pregnancy, also called intrahepatic cholestasis of pregnancy (ICP), is a liver disorder that usually develops in the second or third trimester. It is characterized by impaired bile flow, rising maternal bile acids, and intense itching, often without a primary skin rash. Symptoms commonly affect the palms and soles and may become more noticeable at night.

Although the mother may experience limited physical illness beyond pruritus, the fetus can face meaningful risks. These include spontaneous preterm birth, meconium-stained amniotic fluid, fetal distress, and, in severe cases, stillbirth. Diagnosis and management therefore require attention to both maternal symptoms and biochemical results.

Perinatal specialists assess ICP within the wider context of fetal surveillance, timing of birth, medication safety, and local clinical resources. This focus reflects the broader priorities of the FAOPS 2020 congress, which brought together research and clinical perspectives in perinatal and neonatal medicine before its cancellation during the COVID-19 pandemic.

What causes cholestasis during pregnancy

The exact cause of ICP is not fully understood. Genetic susceptibility, increased pregnancy hormones, and environmental factors appear to interact. Estrogen and progesterone metabolites can affect bile transport within liver cells, while variants in genes involved in bile acid secretion may increase vulnerability. A personal or family history of ICP raises the likelihood of recurrence.

The condition is more common in some geographic and ethnic populations, including parts of South America, South Asia, and Scandinavia. Multiple pregnancy, assisted reproductive technology, a history of liver disease, and previous ICP may also be associated with higher risk. Still, many affected patients have no identifiable risk factor.

Pruritus is the classic symptom. It often begins without visible lesions, although scratching can produce excoriations. Jaundice is less common and may indicate more substantial liver dysfunction or another diagnosis. Dark urine, pale stools, nausea, right upper abdominal pain, or generalized illness should prompt assessment for alternative or additional liver disorders.

How clinicians establish the diagnosis

Diagnosis begins with a careful history and physical examination. Clinicians ask when itching started, where it is located, whether it worsens at night, and whether a rash appeared first. They also review medications, exposure risks for viral hepatitis, previous liver problems, and pregnancy complications. A rash that precedes itching may point toward a dermatologic condition rather than ICP.

The key laboratory test is a serum total bile acid measurement. Liver enzymes, bilirubin, alkaline phosphatase, and other tests help evaluate hepatic function and exclude competing diagnoses, but normal aminotransferases do not rule out ICP. Conversely, elevated liver enzymes can occur in several pregnancy-related and nonpregnancy-related conditions, so results must be interpreted with the clinical picture.

Bile acid concentrations can fluctuate, and itching may begin before the first abnormal result. When symptoms remain strongly suggestive, repeat testing is appropriate rather than dismissing the diagnosis after one normal sample. Testing for hepatitis, gallbladder disease, autoimmune liver disorders, or other causes may be necessary when the presentation is atypical.

Thresholds and treatment protocols vary between guidelines, laboratories, and health systems. A single number should not replace clinical judgment, especially when gestational age, fetal growth, coexisting disease, and access to emergency obstetric care influence decisions.

Why fetal risks require close attention

The maternal symptoms of ICP do not reliably predict fetal status. A patient with tolerable itching may still have significant bile acid elevation, while severe itching can occur with modest laboratory abnormalities. This disconnect is why fetal risk assessment depends on biochemical severity and ongoing obstetric evaluation rather than symptom intensity alone.

The principal fetal concerns are spontaneous preterm labor, iatrogenic preterm birth, meconium passage, and fetal hypoxia. Stillbirth is uncommon overall but becomes more concerning at higher bile acid concentrations, particularly when total bile acids reach or exceed 100 µmol/L. Risk may also change with advancing gestation, although the precise timing of risk is not identical for every pregnancy.

Fetal surveillance may include nonstress testing, biophysical profiles, ultrasound assessment, and monitoring of fetal growth. These tools can identify some signs of compromise, but they cannot guarantee prevention of sudden fetal death associated with ICP. A reassuring test reflects the moment it is performed and does not eliminate the need for a delivery plan.

The pandemic period highlighted how disruptions in antenatal care and international access can influence perinatal outcomes; discussions of COVID-19 and global perinatal mortality also underline the importance of reliable follow-up. For patients with cholestasis, timely blood tests, specialist review, and access to obstetric services are essential parts of risk reduction.

Treatment and antenatal monitoring

Ursodeoxycholic acid is commonly used to relieve maternal itching and improve biochemical markers. It is generally considered compatible with pregnancy, although evidence regarding its ability to prevent stillbirth or other major fetal outcomes remains limited. Treatment should therefore support, not replace, risk assessment and delivery planning.

Symptom relief may also involve emollients, cool baths, loose clothing, and sleep support. Antihistamines can sometimes help with nighttime discomfort, though their effect on the underlying cholestasis is limited. Vitamin K deficiency is uncommon but may be considered when there is prolonged cholestasis, steatorrhea, malabsorption, or abnormal clotting tests.

Follow-up usually includes repeated bile acid and liver function testing, assessment of itching, review of fetal movement, and evaluation for other obstetric complications. The schedule depends on disease severity and local protocols. Patients should receive clear instructions to report reduced fetal movement, vaginal bleeding, fluid leakage, regular contractions, severe abdominal pain, or worsening jaundice immediately.

Antenatal corticosteroids may be offered when early delivery is likely, particularly within the gestational window in which neonatal respiratory complications are a concern. Guidance on antenatal corticosteroid therapy emphasizes that treatment should be timed according to the probability of preterm birth and balanced against gestational age, infection risk, and the clinical circumstances.

Planning birth safely

Delivery timing is individualized. The decision considers peak bile acid concentration, gestational age, symptom trajectory, liver test results, fetal growth, prior obstetric history, and the capabilities of the maternity unit. Many guidelines recommend planned birth during the late preterm or early term period for severe disease, while milder cases may be managed closer to term with ongoing review.

A bile acid level of 100 µmol/L or higher often leads to a stronger discussion of earlier delivery because of the association with stillbirth. For lower levels, the best timing is less uniform, and delivering too early can expose the newborn to respiratory distress, feeding problems, jaundice, infection, and neonatal unit admission. Shared decision-making should explain both the risk of continuing pregnancy and the consequences of preterm birth.

Induction of labor is often possible when there is no obstetric contraindication. Continuous fetal monitoring during labor may be advised, particularly in severe disease or when additional risk factors exist. Meconium-stained fluid should prompt appropriate neonatal readiness, although routine invasive procedures are not justified solely because ICP is present.

After birth, itching and bile acids generally improve, but follow-up remains important. Persistent abnormal liver tests or symptoms may reveal an underlying liver condition. Patients should be informed that recurrence in a future pregnancy is common and that early communication with an obstetric clinician can support prompt testing.

Practical priorities for patients and care teams

Clear communication can reduce delays and help patients understand why laboratory results and delivery planning may change over time. Care should ideally involve obstetricians, midwives, maternal-fetal medicine specialists, laboratory staff, and neonatology teams when early birth is possible.

Useful priorities include:

• Test serum bile acids and liver function when new pregnancy-related itching develops, especially on the palms, soles, or at night.
• Repeat testing when symptoms persist despite an initially normal result.
• Record the highest bile acid level, because peak severity can guide fetal risk assessment and birth timing.
• Provide explicit instructions for urgent review after reduced fetal movement, jaundice, bleeding, fluid leakage, or contractions.
• Arrange postpartum liver testing and discuss the high likelihood of recurrence in a future pregnancy.

Patients should avoid assuming that the absence of a rash makes itching harmless or that a normal fetal monitoring test removes all risk. Conversely, a diagnosis of ICP does not automatically mean immediate delivery. Decisions are safest when made through repeated review of symptoms, laboratory trends, gestational age, and fetal and maternal wellbeing.

Maternal cholestasis deserves prompt evaluation because its warning signs can be subtle while its fetal implications are significant. Anyone who develops unexplained itching during pregnancy should contact a maternity care provider for assessment, repeat testing when appropriate, and a personalized plan for monitoring and birth.